These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [A trial of the use of finasteride and terazosin in patients with benign prostatic hyperplasia].
    Author: Pushkar' DIu, Kosko DV, Loran OB, Kan IaD, Sapozhnikov IM, Tevlin KP.
    Journal: Urol Nefrol (Mosk); 1995; (4):32-5. PubMed ID: 7571199.
    Abstract:
    94 patients with obstructive urination due to benign prostatic hyperplasia received finasteride (proscar), inhibitor of 5 alpha-reductase, in a single dose 5 mg and terazosine, alpha 1 adrenoblocker, in a daily dose of 9.7 mg/day. The follow-up averaged 16.1 months. As shown by overall score of the symptoms and quality of life, rectal and ultrasonic examinations, uroflowmetry, the prostate decreased by 17%, on the average in 72% of the patients. Subjectively, urination has also improved. Maximal flow rate elevated by 55% in the majority of patients. Combination of finasterine with terazosine is well tolerated and proved optimal as a conservative therapy in patients with obstructive urination as a result of benign prostatic hyperplasia.
    [Abstract] [Full Text] [Related] [New Search]